Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio

Drug Profile

Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio

Alternative Names: Anti-G protein-coupled receptor antibodies - Ab3; Anti-G protein-coupled receptor antibodies - Ab6; Anti-G protein-coupled receptor antibodies - CCR7; Anti-G protein-coupled receptor antibodies - EP2; Anti-G protein-coupled receptor antibodies - EP4

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Abilita Bio
  • Class Antibodies
  • Mechanism of Action CCR7 receptor modulators; G protein-coupled receptor antagonists; Prostaglandin E EP2 receptor modulators; Prostaglandin E EP4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer; Cancer; CNS disorders

Most Recent Events

  • 22 Sep 2016 Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio is available for licensing as of 22 Sep 2016. http://www.abilitabio.com/
  • 20 Sep 2016 Abilita Bio enters into a multi-target proof of concept agreement with an undisclosed global pharmaceutical company
  • 20 Sep 2016 Abilita Bio receives SBIR grant from National Cancer Institute (NCI) for anti-G protein-coupled receptor antibodies development in Breast cancer (Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top